Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study.

Langhorne P, O'Donnell MJ, Chin SL, Zhang H, Xavier D, Avezum A, Mathur N, Turner M, MacLeod MJ, Lopez-Jaramillo P, Damasceno A, Hankey GJ, Dans AL, Elsayed A, Mondo C, Wasay M, Czlonkowska A, Weimar C, Yusufali AH, Hussain FA, Lisheng L, Diener HC, Ryglewicz D, Pogosova N, Iqbal R, Diaz R, Yusoff K, Oguz A, Wang X, Penaherrera E, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Magazi D, Nilanont Y, Rosengren A, Oveisgharan S, Yusuf S; INTERSTROKE collaborators.

Lancet. 2018 May 19;391(10134):2019-2027. doi: 10.1016/S0140-6736(18)30802-X. Epub 2018 May 17.

PMID:
29864018
2.

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S; COMPASS investigators.

Lancet. 2018 Jan 20;391(10117):205-218. doi: 10.1016/S0140-6736(17)32458-3. Epub 2017 Nov 10. Erratum in: Lancet. 2017 Dec 21;:.

PMID:
29132879
3.

Outline of the report on cardiovascular diseases in China, 2014.

Weiwei C, Runlin G, Lisheng L, Manlu Z, Wen W, Yongjun W, Zhaosu W, Huijun L, Zhe Z, Lixin J, Shengshou H.

Eur Heart J Suppl. 2016 May;18(Suppl F):F2-F11. doi: 10.1093/eurheartj/suw030. Epub 2016 May 24.

PMID:
28533724
4.

Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes.

Mohammedi K, Woodward M, Hirakawa Y, Zoungas S, Williams B, Lisheng L, Rodgers A, Mancia G, Neal B, Harrap S, Marre M, Chalmers J; ADVANCE Collaborative Group.

Diabetes Care. 2016 Oct;39(10):1796-803. doi: 10.2337/dc16-0588. Epub 2016 Jul 25.

PMID:
27456835
5.

Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes.

Hirakawa Y, Arima H, Webster R, Zoungas S, Li Q, Harrap S, Lisheng L, Hamet P, Mancia G, Poulter N, Neal B, Williams B, Rogers A, Woodward M, Chalmers J.

J Hypertens. 2016 Apr;34(4):781-7. doi: 10.1097/HJH.0000000000000841.

6.

Restructuring Hypertension Congresses and Scientific Meetings for Improved Hypertension Prevention and Control.

Campbell NR, Redburn KA, Niebylski ML, Drouin D, Zhang XH, Lisheng L, Nilsson P, Lackland DT; World Hypertension League, Corvallis, Montana, USA.

J Clin Hypertens (Greenwich). 2016 Mar;18(3):169-71. doi: 10.1111/jch.12748. Epub 2015 Dec 11. No abstract available.

7.

Implementation of World Health Organization Package of Essential Noncommunicable Disease Interventions (WHO PEN) for Primary Health Care in Low-Resource Settings: A Policy Statement From the World Hypertension League.

Zhang XH, Lisheng L, Campbell NR, Niebylski ML, Nilsson P, Lackland DT; World Hypertension League.

J Clin Hypertens (Greenwich). 2016 Jan;18(1):5-6. doi: 10.1111/jch.12749. Epub 2015 Dec 8. No abstract available.

8.

World Hypertension League Position on Public Use of Blood Pressure Kiosks.

Campbell NR, Niebylski ML, Redburn K, Lisheng L, Nilsson P, Zhang XH, Lackland DT.

J Clin Hypertens (Greenwich). 2015 Dec;17(12):913. doi: 10.1111/jch.12671. Epub 2015 Sep 20. No abstract available.

9.

The World Hypertension League: where now and where to in salt reduction.

Campbell NR, Lackland DT, Lisheng L, Zhang XH, Nilsson PM, Niebylski ML; World Hypertension League Executive.

Cardiovasc Diagn Ther. 2015 Jun;5(3):238-42. doi: 10.3978/j.issn.2223-3652.2015.04.08.

10.

The World Hypertension League challenges hypertension and cardiovascular organizations to develop strategic plans for the prevention and control of hypertension.

Campbell NR, Lackland DT, Lisheng L, Zhang XH, Nilsson PM, Redburn KA, Niebylski ML.

J Clin Hypertens (Greenwich). 2015 May;17(5):325-7. doi: 10.1111/jch.12557. Epub 2015 Apr 10. No abstract available.

11.

Using the Global Burden of Disease study to assist development of nation-specific fact sheets to promote prevention and control of hypertension and reduction in dietary salt: a resource from the World Hypertension League.

Campbell NR, Lackland DT, Lisheng L, Niebylski ML, Nilsson PM, Zhang XH.

J Clin Hypertens (Greenwich). 2015 Mar;17(3):165-7. doi: 10.1111/jch.12479. Epub 2015 Jan 31.

12.

The World Hypertension League: a look back and a vision forward.

Campbell NC, Lackland DT, Lisheng L, Zhang XH, Nilsson PM, Redburn KA, Niebylski ML.

J Clin Hypertens (Greenwich). 2015 Jan;17(1):5-6. doi: 10.1111/jch.12469. Epub 2014 Dec 30. No abstract available.

13.

A needs assessment of national hypertension organizations for hypertension prevention and control programs.

Khalsa TK, Campbell NR, Lackland DT, Lisheng L, Niebylski ML, Zhang XH.

J Clin Hypertens (Greenwich). 2014 Dec;16(12):848-55. doi: 10.1111/jch.12432. Epub 2014 Nov 10. No abstract available.

14.

Updated national and international hypertension guidelines: a review of current recommendations.

Kjeldsen S, Feldman RD, Lisheng L, Mourad JJ, Chiang CE, Zhang W, Wu Z, Li W, Williams B.

Drugs. 2014 Nov;74(17):2033-51. doi: 10.1007/s40265-014-0306-5. Review.

15.

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.

Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M; ADVANCE-ON Collaborative Group.

N Engl J Med. 2014 Oct 9;371(15):1392-406. doi: 10.1056/NEJMoa1407963. Epub 2014 Sep 19.

16.

The International Society of Hypertension and World Hypertension League call on governments, nongovernmental organizations and the food industry to work to reduce dietary sodium.

Campbell NR, Lackland DT, Chockalingam A, Lisheng L, Harrap SB, Touyz RM, Burrell LM, Ramírez AJ, Schmieder RE, Schutte AE, Prabhakaran D, Schiffrin EL; Executive Board of the World Hypertension League:; Executive Committee of the International Society of Hypertension:.

J Hypertens. 2014 Feb;32(2):446-7. doi: 10.1097/HJH.0000000000000079.

PMID:
24430121
17.

The World Hypertension League and International Society of Hypertension call on governments, nongovernmental organizations, and the food industry to work to reduce dietary sodium.

Campbell N, Lackland D, Chockalingam A, Lisheng L, Schiffrin EL, Harrap S, Touyz RM, Burrell L, Ramírez A, Schmieder R, Aletta S, Prabhakaran D.

J Clin Hypertens (Greenwich). 2014 Feb;16(2):99-100. doi: 10.1111/jch.12245. Epub 2014 Jan 15. No abstract available. Erratum in: J Clin Hypertens (Greenwich). 2016 Apr;18(4):366.

18.

Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation".

Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz J, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB.

Circulation. 2014 Jan 14;129(2):e21-2. doi: 10.1161/CIRCULATIONAHA.113.005709. No abstract available.

PMID:
24421367
19.

World health day.

Lisheng L, Campbell N, Chockalingam A; World Hypertension League.

Glob Heart. 2013 Jun;8(2):183. doi: 10.1016/j.gheart.2013.04.002. No abstract available.

20.

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.

Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators.

Circulation. 2013 Jun 4;127(22):2166-76. doi: 10.1161/CIRCULATIONAHA.112.142158. Epub 2013 May 2.

PMID:
23640971

Supplemental Content

Loading ...
Support Center